Amyloid-beta metal interaction and metal chelation.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical mechanisms without systematic review methodology or primary clinical trial data
PubMed 15709482 · doi:10.1007/0-387-23226-5_12
What was done
This narrative review synthesized evidence regarding the interactions of amyloid-beta (Abeta) and amyloid precursor protein (APP) with metal ions (zinc, copper, and iron), the role of metal dyshomeostasis in Alzheimer's disease pathology, and the preclinical utility of metal chelating agents.
What was found
The abstract provides no numerical data. It qualitatively reports that metal ions facilitate Abeta precipitation and cytotoxicity, and that metal-chelating compounds have been shown to reverse amyloid-beta plaque deposition in in vitro and in vivo models.
Why it matters
It outlines the mechanistic rationale for targeting biometal-Abeta interactions as a disease-modifying therapeutic approach in Alzheimer's disease.
Limits
As a narrative review, it lacks systematic search methodology, quantitative meta-analyses, and direct human clinical trial outcome data. Specific chelating agents, dosages, and safety profiles are not detailed in the abstract.
Cited by
- supports Research by Ashley Bush showed that amyloid-beta binds divalent metals including copper, zinc, and iron.